[Prognostic value of pulmonary hypertension in patients with severe COPD]. 1996

G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
Kliniki Chorób Płuc Instytutu Gruźlicy, Warszawie.

There is a continuing debate on the role of pulmonary hypertension in the natural history of COPD. The aim of the study was to compare 2 groups of COPD pts, one investigated before domiciliary oxygen treatment era (Group I) with the other benefiting from LTOT (Group II). Both were followed-up for 5 years. METHODS pure COPD, PaO2 < 60 mmHg, PAP > 20 mmHg. Group I consisted of 16 pts (13M, 3F), mean age 55 +/- 9y. On initial evaluation their FEV1 averaged 0.93 +/- 0.3L and PaO2 54 +/- 6 mmHg. Their mean pulmonary arterial pressure (PAP) was 37.9 +/- 9 mmHg. During five years 12 patients (75%) died. Mean survival time of pts who died was 18.9 +/- 14.7 months. Group II consisted of 34 pts (27M, 7F) mean age 56 +/- 8y (NS vs group I), FEVI 0.83 +/- 3L (NS). PaO2 53 +/- 6 mmHg (NS), PAP 30.9 +/- 8.5 mmHg (p < 0.02). During five years 26 pts (76.5%) died. Mean survival time was 25 +/- 16 months (NS). Mean oxygen breathing time was 14h/ day. The Cox's survival analysis did not show difference between patients group I and II. We conclude that high initial PAP in group I patients did not affect survival compared to patients with similar severity of respiratory failure and lower PAP. The finding that LTOT did not improve survival may depend on many other variables not included into analysis.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008173 Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010102 Oxygen Inhalation Therapy Inhalation of oxygen aimed at restoring toward normal any pathophysiologic alterations of gas exchange in the cardiopulmonary system, as by the use of a respirator, nasal catheter, tent, chamber, or mask. (From Dorland, 27th ed & Stedman, 25th ed) Inhalation Therapy, Oxygen,Therapy, Oxygen Inhalation,Inhalation Therapies, Oxygen,Oxygen Inhalation Therapies,Therapies, Oxygen Inhalation
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
July 2019, Chest,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
January 2000, Annals of transplantation,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
September 2016, Thorax,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
October 2011, The Journal of thoracic and cardiovascular surgery,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
June 2012, BMC pulmonary medicine,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
July 2023, The European respiratory journal,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
September 2014, Heart, lung & circulation,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
January 2019, Pulmonary circulation,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
September 2015, Tuberkuloz ve toraks,
G Pałasiewicz, and P Sliwiński, and I Hawryłkiewicz, and M Tobiasz, and J Zieliński
March 2023, Life (Basel, Switzerland),
Copied contents to your clipboard!